Cerebral Atherosclerosis Research With Positron Emission Tomography

NCT07041372 | Enrolling By Invitation DMC

• 1 other identifier: CARPET
• Study Type: observational
• Target: 310
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

• Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
• Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients. Participants will:
• Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
• Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
• Maintain regular clinic visits for up to 24 months following the index stroke

Conditions

Cerebral Infarction

Keywords

cerebral infarction

Outcome Measures

Primary Outcomes (1)

• Vascular events

  Stroke, myocardial infarction, vascular death

  up to 24 months after index stroke

Secondary Outcomes (1)

• overall vascular events

  up to 24 months after index stroke

Other Outcomes (1)

• Overall events

  up to 24 months after index stroke

Interventions

FDG-PET DIAGNOSTIC_TEST

The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients aged 19 years and older who were diagnosed and treated for acute cerebral infarction within 7 days and can voluntarily participate in the study.

You may qualify if:

• acute ischemic stroke patients who admitted within seven days after symptom onset

You may not qualify if:

• Patients with unstable vital signs or neurological symptoms
• Patients with estimated glomerular filtration rate less than 30ml/min
• Patients with uncontrolled diabetes requiring persistent insulin injection
• During pregnancy or while breastfeeding
• Patients with impaired consent capacity
• Patients with diagnosed/treatment for dementia
• Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Sponsors & Collaborators

• Seoul National University Hospital: lead

Study Sites (1)

Seoul National University Hospital

Seoul, Jong-ro Gu, 03080, South Korea

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

venous blood

MeSH Terms

Conditions

Cerebral Infarction

Condition Hierarchy (Ancestors)

Brain Infarction; Brain Ischemia; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Vascular Diseases; Cardiovascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 19, 2025
• First Posted: June 27, 2025
• Study Start: June 22, 2021
• Primary Completion (Estimated): February 28, 2029
• Study Completion (Estimated): August 31, 2029
• Last Updated: June 27, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)